1. Home
  2. ZNTL vs NCV Comparison

ZNTL vs NCV Comparison

Compare ZNTL & NCV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ZNTL
  • NCV
  • Stock Information
  • Founded
  • ZNTL 2014
  • NCV 2003
  • Country
  • ZNTL United States
  • NCV United States
  • Employees
  • ZNTL N/A
  • NCV N/A
  • Industry
  • ZNTL Biotechnology: Pharmaceutical Preparations
  • NCV Finance Companies
  • Sector
  • ZNTL Health Care
  • NCV Finance
  • Exchange
  • ZNTL Nasdaq
  • NCV Nasdaq
  • Market Cap
  • ZNTL 300.4M
  • NCV 300.0M
  • IPO Year
  • ZNTL 2020
  • NCV N/A
  • Fundamental
  • Price
  • ZNTL $3.70
  • NCV $3.43
  • Analyst Decision
  • ZNTL Buy
  • NCV
  • Analyst Count
  • ZNTL 7
  • NCV 0
  • Target Price
  • ZNTL $13.14
  • NCV N/A
  • AVG Volume (30 Days)
  • ZNTL 1.6M
  • NCV 405.1K
  • Earning Date
  • ZNTL 08-07-2024
  • NCV 01-01-0001
  • Dividend Yield
  • ZNTL N/A
  • NCV 12.48%
  • EPS Growth
  • ZNTL N/A
  • NCV N/A
  • EPS
  • ZNTL N/A
  • NCV N/A
  • Revenue
  • ZNTL $40,560,000.00
  • NCV N/A
  • Revenue This Year
  • ZNTL N/A
  • NCV N/A
  • Revenue Next Year
  • ZNTL N/A
  • NCV N/A
  • P/E Ratio
  • ZNTL N/A
  • NCV N/A
  • Revenue Growth
  • ZNTL N/A
  • NCV N/A
  • 52 Week Low
  • ZNTL $3.27
  • NCV $2.84
  • 52 Week High
  • ZNTL $29.03
  • NCV $3.59
  • Technical
  • Relative Strength Index (RSI)
  • ZNTL 30.12
  • NCV 66.97
  • Support Level
  • ZNTL $3.83
  • NCV $3.33
  • Resistance Level
  • ZNTL $4.79
  • NCV $3.47
  • Average True Range (ATR)
  • ZNTL 0.44
  • NCV 0.05
  • MACD
  • ZNTL 0.26
  • NCV 0.01
  • Stochastic Oscillator
  • ZNTL 28.29
  • NCV 81.82

About ZNTL Zentalis Pharmaceuticals Inc.

Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. It uses a drug discovery engine, which it refers to as an Integrated Discovery Engine, to identify targets and develop small molecule new chemical entities, or NCEs, with properties that it believes could result in potentially differentiated product profiles. It has two lead product candidates under pipeline: ZN-c5, for the treatment of advanced estrogen receptor-positive, human epidermal growth factor receptor 2-negative, or ER+/HER2-, advanced or metastatic breast cancer; and ZN-c3, for the treatment of advanced solid tumors as monotherapy and ovarian cancer.

About NCV Virtus Convertible & Income Fund of Beneficial Interest

Virtus Convertible & Income Fund is a diversified, closed-end management investment company. Its investment objective is to provide total return through a combination of capital appreciation and high current income. It intends to achieve the objective by investing in a portfolio of domestic convertible securities and non-convertible income-producing securities. Its portfolio of investments includes Software, the Internet, the Commercial Services sector in the form of Convertible Bonds and Notes, and Media, Oil, Gas & Consumable Fuels, and Entertainment sector in the form of Corporate Bonds and Notes.

Share on Social Networks: